656820-32-5
中文名稱
REVERSINE
英文名稱
REVERSINE
CAS
656820-32-5
分子式
C21H27N7O
分子量
393.49
MOL 文件
656820-32-5.mol
更新日期
2025/02/05 09:52:11
656820-32-5 結(jié)構(gòu)式
基本信息
中文別名
逆轉(zhuǎn)素逆轉(zhuǎn)素, >96%
AURORA激酶抑制劑(REVERSINE)
N6-環(huán)己基-N2-(4-嗎啉苯基)-9H-嘌呤-2,6-二胺
英文別名
CS-870REVERSINE
Reversine, >96%
Reversine, >=98%
REVERSINE USP/EP/BP
Picropodophyllin (PPP)
2-(4-MORPHOLINOANILINO)-6-CYCLOHEXYLAMINOPURINE
N6-CYCLOHEXYL-N2-(4-MORPHOLINOPHENYL)-9H-PURINE-2,6-DIAMINE
N6-Cyclohexyl-N2-(4-morpholinophenyl)-7H-purine-2,6-diamine
N6-CYCLOHEXYL-N2-[4-(4-MORPHOLINYL)PHENYL]-1H-PURINE-2,6-DIAMINE
所屬類別
生物化工：蛋白酪氨酸激酶物理化學(xué)性質(zhì)
熔點(diǎn)305℃ (decomposition)
沸點(diǎn)736.4±70.0 °C(Predicted)
密度1.343±0.06 g/cm3(Predicted)
儲(chǔ)存條件2-8°C
溶解度DMSO: 7 mg/mL, soluble
酸度系數(shù)(pKa)10.51±0.10(Predicted)
形態(tài)solid
顏色米白色
穩(wěn)定性從購(gòu)買(mǎi)之日起 2 年內(nèi)保持穩(wěn)定。 DMSO 溶液可在 -20°C 下保存長(zhǎng)達(dá) 3 個(gè)月
安全數(shù)據(jù)
警示詞警告
危險(xiǎn)性描述H302
防范說(shuō)明P264-P270-P301+P312-P330-P501
危險(xiǎn)品標(biāo)志Xn
危險(xiǎn)類別碼22
WGK Germany3
常見(jiàn)問(wèn)題列表
生物活性
Reversine是一種強(qiáng)效human A3 adenosine receptor拮抗劑，Ki為0.66 μM，也是一種泛aurora A/B/C kinase抑制劑，IC50分別為12 nM/13 nM/20 nM。也用于干細(xì)胞分化。體外研究
Reversine induces myogenic lineage-committed cells to become multipotent mesenchymal progenitor cells, which proliferates and redifferentiates into bone and fat cells. Reversine, as an A3 adenosine receptor antagonist, competitively inhibits forskolin-stimulated cAMP production in stably transfected Chinese hamster ovary (CHO) cells. Reversine inhibits the phosphorylation of a well-known Aurora target, histone H3 in HCT116 cells. Moreover, Reversine potently blocks proliferation of multiple tumor cell types, and induces cell death. In primary human tumor samples, Reversine also inhibits colony formation of leukemic cells. When treated in combination, reversine and aspirin synergistically inhibit growth of cervical cancer cells and induce cell apoptosis.體內(nèi)研究
In mice inoculated with U14 tumors, Reversine (10 mg/kg i.p.) and aspirin cause more reduced tumor weight and tumor volume when compared with the control agents.